Functional liquid biopsy, across a broad range of diseases
Aqtual reads active-chromatin cfDNA to measure the functional direction of disease, the signal behind earlier detection, sharper stratification, and faster development across chronic disease, from autoimmune and inflammatory conditions to oncology and beyond.
Aqtual at a glance.
Silicon Valley, California
Journals & major congresses
Rheumatoid arthritis · PRIMA-102 (NCT05936970)
Autoimmune, oncology, and beyond
Total capital raised
Named partners below
Company milestones.
Selected milestones from Aqtual's newsroom, from first financing to the latest clinical and platform data.
Aqtual announced the appointments of Ferhan Qureshi as Chief Technology Officer and Bill Arteca as Head of Biospecimen Strategy to support the development of its active chromatin cfDNA diagnostics.
Aqtual appointed Daniil Kalyuzhny as Chief Financial Officer to lead the company's next phase of strategic growth and clinical validation of its therapy-selection tests.
A study published in Nature – npj Precision Oncology details the use of active chromatin cfDNA profiling to predict immunotherapy benefits and identify resistance mechanisms in leiomyosarcoma.
Aqtual secured $31 million in an oversubscribed Series B funding round to advance its cell-free DNA-based therapy response prediction assay for rheumatoid arthritis toward commercialization.
A team of veteran diagnostics leaders.
Founded and advised by veteran diagnostics, rheumatology, and oncology leaders, the people who built and scaled precision-medicine programs before Aqtual.
Institutional investors.
Aqtual is backed by life-science and deep-tech investors who share a long-term view that precision medicine can radically address the challenges facing human health.
Inside our facility.
Build with us.
A lean, nimble team located in Hayward, CA bringing together biochemistry, computational biology, clinical operations, and data science. If you want your work to reach patients and make a difference, we'd like to hear from you.
Investor relations.
For financing, partnership, or investor materials, reach our team directly. We respond within 24 hours during our business hours, Monday through Friday, 9:00 AM to 5:00 PM Pacific Time.
Looking for our investor materials? Request them here.